Furthermore, when the SBII:2pre trial was conducted, the overall prognosis for premenopausal breast cancer patients was worse than today, that is HER2-positive patients included did not receive trastuzumab, which would have affected their prognosis [33]. The gene discussed is ERBB2; the disease is breast cancer.